<DOC>
	<DOCNO>NCT02077452</DOCNO>
	<brief_summary>The objective study determine safety , tolerability , pharmacokinetics pharmacodynamics HMS5552 follow multiple ascend dos patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics HMS5552 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This randomize , double-blind placebo-controlled study multiple oral dos HMS5552 give patient type 2 diabetes mellitus never accept anti-diabetic drug treatment . The primary objective characterize safety tolerability HMS5552 follow multiple ascend dos patient type 2 diabetes mellitus BID dose 8 day . The secondary objective include : 1 . To determine single dose steady state pharmacokinetics HMS5552 patient type 2 diabetes 2 . To evaluate single dose steady state pharmacodynamics HMS5552 patient type 2 diabetes 3 . To explore food-effect HMS5552 pharmacokinetics pharmacodynamics A maximum total 80 patient ( 10 dose group assume maximum 5~8 dose level ) . There 8 active 2 placebo patient dose group . The safety , tolerability , pharmacokinetics pharmacodynamics data dose cohort review blinded fashion escalation next dose cohort .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject type 2 diabetes Age : 18 65 year BMI : 20 29 kg/m2 Mentally , physically legally eligible give inform consent . Willingness adhere protocol requirement . Subjects type 1 diabetes Episodes hypoglycemia Unstable cardiovascular disease Hepatic diseases Kidney disease Mental central nervous system diseases Clinical abnormal finding ECG , labs physical exam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Glucokinase activator</keyword>
	<keyword>Phase I</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>